CRISPR Therapeutics AG [NASDAQ: CRSP] jumped around 6.63 points on Tuesday, while shares priced at $121.67 at the close of the session, up 5.76%. The company report on April 20, 2021 that Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia.
– Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-.
– Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics-.
CRISPR Therapeutics AG stock is now -20.53% down from its year-to-date (YTD) trading value. CRSP Stock saw the intraday high of $125.48 and lowest of $117.38 per share. The company’s 52-week high price is 220.20, which means current price is +21.67% above from all time high which was touched on 01/15/21.
Compared to the average trading volume of 2.05M shares, CRSP reached a trading volume of 2619435 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CRISPR Therapeutics AG [CRSP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $157.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on March 04, 2021. While these analysts kept the previous recommendation, Needham raised their target price from $105 to $170. The new note on the price target was released on December 10, 2020, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another raise from $110 to $166, while Chardan Capital Markets kept a Buy rating on CRSP stock.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 7.54, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 13694.83. The Price to Book ratio for the last quarter was 5.22, with the Price to Cash per share for the same quarter was set at 21.45.
How has CRSP stock performed recently?
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.65. With this latest performance, CRSP shares dropped by -6.13% in over the last four-week period, additionally plugging by 10.78% over the last 6 months – not to mention a rise of 127.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 48.99, with the RSI for the last a single of trading hit 52.30, and the three-weeks RSI is set at 46.95 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 129.36, while it was recorded at 120.45 for the last single week of trading, and 119.25 for the last 200 days.
CRISPR Therapeutics AG [CRSP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CRISPR Therapeutics AG [CRSP] shares currently have an operating margin of -49295.55. CRISPR Therapeutics AG’s Net Margin is presently recorded at -48520.86.
Return on Total Capital for CRSP is now -26.08, given the latest momentum, and Return on Invested Capital for the company is -25.86. Return on Equity for this stock declined to -26.80, with Return on Assets sitting at -24.10. When it comes to the capital structure of this company, CRISPR Therapeutics AG [CRSP] has a Total Debt to Total Equity ratio set at 3.69. Additionally, CRSP Total Debt to Total Capital is recorded at 3.56, with Total Debt to Total Assets ending up at 3.36. Long-Term Debt to Equity for the company is recorded at 3.01, with the Long-Term Debt to Total Capital now at 2.90.
Reflecting on the efficiency of the workforce at the company, CRISPR Therapeutics AG [CRSP] managed to generate an average of -$850,890 per employee. Receivables Turnover for the company is 0.10 with a Total Asset Turnover recorded at a value of 0.00.CRISPR Therapeutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.20 and a Current Ratio set at 18.20.
Earnings analysis for CRISPR Therapeutics AG [CRSP]
With the latest financial reports released by the company, CRISPR Therapeutics AG posted -1.15/share EPS, while the average EPS was predicted by analysts to be reported at -1.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRSP.
Insider trade positions for CRISPR Therapeutics AG [CRSP]
There are presently around $5,733 million, or 64.20% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 10,412,976, which is approximately 23.124% of the company’s market cap and around 1.20% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 7,426,716 shares of the stock with an approximate value of $903.61 million in CRSP stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $466.83 million in CRSP stock with ownership of nearly 3.763% of the company’s market capitalization.
Positions in CRISPR Therapeutics AG stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 265 institutional holders increased their position in CRISPR Therapeutics AG [NASDAQ:CRSP] by around 5,611,573 shares. Additionally, 127 investors decreased positions by around 5,917,941 shares, while 49 investors held positions by with 35,585,670 shares. The mentioned changes placed institutional holdings at 47,115,184 shares, according to the latest SEC report filing. CRSP stock had 126 new institutional investments in for a total of 869,959 shares, while 36 institutional investors sold positions of 2,422,591 shares during the same period.